Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chromosome 11

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Chromosome 11. Displaying page 6 of 6.
    « Previous 1  2  3  4  5  6 
    EudraCT Number: 2015-005399-12 Sponsor Protocol Number: DKMS-16-01 Start Date*: 2017-08-02
    Sponsor Name:DKMS gemeinnützige GmbH
    Full Title: A randomized controlled trial comparing outcome after hematopoietic cell transplantation from a partially matched unrelated versus haploidentical donor
    Medical condition: Patients with high-risk AML, ALL or MDS which have to undergo allogenic transplantaion.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024349 Leukemia myeloid LLT
    20.0 100000004864 10024337 Leukemia lymphatic LLT
    20.0 100000004864 10068361 MDS LLT
    20.1 100000004864 10024330 Leukemia acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000826-31 Sponsor Protocol Number: NN7999-3774 Start Date*: 2012-08-24
    Sponsor Name:Novo Nordisk
    Full Title: Safety, Efficacy and Pharmacokinetics of NNC-0156- 0000-0009 (N9-GP) in Previously Treated Children with Haemophilia B
    Medical condition: Haemophilia B
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003417-35 Sponsor Protocol Number: PARPA-293-002 Start Date*: 2021-11-10
    Sponsor Name:Nerviano Medical Sciences S.r.l
    Full Title: A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
    Medical condition: Glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-001657-26 Sponsor Protocol Number: KCH-BMT-07-1.0 Start Date*: 2008-02-29
    Sponsor Name:King's College Hospital NHS Foundation Trust
    Full Title: Single Centre Phase II Pilot study of Unrelated Cord Blood Transplantation in Patients with Poor Risk Haematological Malignancies.
    Medical condition: 1. Acute, chronic leukaemia or myelodysplastic syndrome for which allogeneic transplantation is considered as the best treatment option. 2. Acute lymphoblastic leukaemia (ALL) 3. Non-Hodgkin’s l...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000880 Acute myeloid leukaemia LLT
    9.1 10028533 Myelodysplastic syndrome LLT
    9.1 10009013 Chronic myeloid leukaemia LLT
    9.1 10000844 Acute lymphoblastic leukaemia LLT
    9.1 10020328 Hodgkin's lymphoma LLT
    9.1 10029593 Non-Hodgkin's lymphoma NOS LLT
    9.1 10003892 B-cell chronic lymphocytic leukaemia/prolymphocytic leukaemia/small lymphocytic lymphoma LLT
    9.1 10002968 Aplastic anaemia, unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-001697-17 Sponsor Protocol Number: R1979-ONC-1504 Start Date*: 2015-12-01
    Sponsor Name:Regeneron Pharmaceuticals, Inc
    Full Title: A Phase 1 Study to Assess Safety and Tolerability of REGN1979, an anti-CD20 x anti- CD3 bispecific monoclonal antibody, and REGN2810, an anti-programmed death-1 monoclonal antibody, in Patients wit...
    Medical condition: B-cell malignancies
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003917 B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026945 Mature B-cell type acute leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067184 Burkitt's leukaemia PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003890 B precursor type acute leukaemia PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003902 B-cell lymphoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2006-000564-81 Sponsor Protocol Number: EGF106903 Start Date*: 2008-01-14
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A randomised, multicentre, open-label, phase III study of neoadjuvant lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2/ErbB2 positive primary breast cancer
    Medical condition: Women with primary ErbB2 overexpressing and/or gene amplified breast cancer > 2 cm diameter who have not undergone previous treatment for invasive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057654 Breast cancer female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) GB (Completed) LT (Completed) GR (Prematurely Ended) HU (Completed) ES (Completed) IT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000995-33 Sponsor Protocol Number: EuroNet-PHL-C1 Start Date*: 2006-12-13
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: 1st and 2nd line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (Completed) SE (Completed) AT (Completed) FR (Completed) IE (Completed) ES (Completed) DK (Completed) PL (Completed) BE (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 14:22:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA